Callan JMB (CJMB) CMO adds 14,805 shares in open-market buy

Rhea-AI Filing Summary

CALLAN JMB INC. Chief Medical Officer and 10% owner David J. Croyle reported an indirect open-market purchase of 14,805 shares of Common Stock at $1.762 per share through a Rollover IRA on March 6, 2026. Following this transaction, his indirect holdings total 789,805 shares, making this a relatively small addition to an already substantial position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Croyle David J

(Last) (First) (Middle)

C/O CALLAN JMB INC.

244 FLIGHTLINE DRIVE

(Street)

SPRING BRANCH TX 78070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CALLAN JMB INC. [ CJMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		P		14,805	A	$1.762	789,805	I	By Rollover IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David J. Croyle	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CJMB disclose for David J. Croyle?

CALLAN JMB INC. reported that Chief Medical Officer David J. Croyle executed an indirect open-market purchase of 14,805 Common Stock shares. The transaction was made through a Rollover IRA and is classified as a non-derivative acquisition in a Form 4 filing.

How many CALLAN JMB INC. (CJMB) shares did the CMO buy and at what price?

David J. Croyle acquired 14,805 shares of CALLAN JMB INC. Common Stock at a purchase price of $1.762 per share. The transaction was reported as an open-market purchase and is categorized as a non-derivative transaction in the Form 4.

What are David J. Croyle’s total CALLAN JMB INC. holdings after this Form 4 transaction?

After the reported purchase, David J. Croyle indirectly holds 789,805 shares of CALLAN JMB INC. Common Stock. These shares are reported as being held through a Rollover IRA, reflecting his post-transaction ownership position in the company.

Is the CJMB insider transaction held directly or indirectly by David J. Croyle?

The reported CJMB transaction is held indirectly by David J. Croyle. The Form 4 specifies ownership type as indirect, with the nature of ownership described as “By Rollover IRA,” indicating the shares are held through that retirement account.

What does the transaction code on the CJMB Form 4 filing indicate?

The Form 4 uses transaction code “P,” which the filing describes as a purchase in an open market or private transaction. This confirms the 14,805 CALLAN JMB INC. shares were bought, not sold, as part of a non-derivative open-market purchase.

Does the CJMB Form 4 indicate whether derivatives were involved in the transaction?

The CJMB Form 4 classifies the reported activity as a non-derivative transaction in Common Stock, and the derivative position summary is empty. This means the disclosed purchase did not involve options, warrants, or other derivative securities in this filing.